John Grundy, PhD
Dr. John S. Grundy received his B.Sc. in Pharmacy and Ph.D. in Pharmaceutical Sciences (specializing in Pharmacokinetics) from the University of Alberta in 1990 and 1996, respectively. He has 21 years of experience working in the pharmaceutical industry for small (Regulus Therapeutics, Orexigen, Neurocrine, GloboMax), medium (Elan Pharmaceuticals, Ionis Pharmaceuticals), and large (Eli Lilly & Company, GlaxoWellcome) pharmaceutical companies. Immediately prior to co-founding DTx Pharma LLC, Dr. Grundy was Vice President of DMPK, Toxicology, & Clinical Pharmacology at Regulus Therapeutics (2014–2017) and before that was Vice President of DMPK & Clinical Pharmacology at Ionis Pharmaceuticals (2008–2014). Dr. Grundy has worked on the development and successful regulatory approval of compounds from various therapeutic/chemical platforms (small molecules including Zonegran® and Contrave®, biologics including Tysabri® and Prialt®, and nucleic acid therapeutics including Kynamro® and Spinraza®) and tested compounds given by various routes/sites of administration (oral, IV, SC, ocular, CNS, etc.).